| Autor: |
Margaret F. Meagher, Maria C. Mir, Andrea Minervini, Maximilian Kriegmair, Matthias Heck, Francesco Porpiglia, Siska Van Bruwaene, Estefania Linares, Vital Hevia, Maurizio D’Anna, Alessandro Veccia, Eduard Roussel, Francesco Claps, Carlotta Palumbo, Michele Marchioni, Jonathan Afari, Cesare Saitta, Franklin Liu, Jose Rubio, Riccardo Campi, Andrea Mari, Thomas Amiel, Enrico Checcucci, Mireia Musquera, Georgi Guruli, Nicola Pavan, Maarten Albersen, Alessandro Antonelli, Tobias Klatte, Riccardo Autorino, Rana R. McKay, Ithaar H. Derweesh |
| Jazyk: |
angličtina |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
Frontiers in Oncology, Vol 13 (2023) |
| Druh dokumentu: |
article |
| ISSN: |
2234-943X |
| DOI: |
10.3389/fonc.2023.1113246 |
| Popis: |
PurposeWe hypothesized that two-tier re-classification of the “M” (metastasis) domain of the Tumor-Node-Metastasis (TNM) staging of Renal Cell Carcinoma (RCC) may improve staging accuracy than the current monolithic classification, as advancements in the understanding of tumor biology have led to increased recognition of the heterogeneous potential of metastatic RCC (mRCC).MethodsMulticenter retrospective analysis of patients from the REMARCC (REgistry of MetAstatic RCC) database. Patients were stratified by number of metastases into two groups, M1 (≤3, “Oligometastatic”) and M2 (>3, “Polymetastatic”). Primary outcome was overall survival (OS). Secondary outcomes were cancer-specific survival (CSS). Cox-regression and Kaplan-Meier (KMA) analysis were utilized for outcomes, and receiver operating characteristic analysis (ROC) was utilized to assess diagnostic accuracy compared to current “M” staging.Results429 patients were stratified into proposed M1 and M2 groups (M1 = 286/M2 = 143; median follow-up 19.2 months). Cox-regression revealed M2 classification as an independent risk factor for worsened all-cause mortality (HR=1.67, p=0.001) and cancer-specific mortality (HR=1.74, p |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
